Nadav Kidron

Now, in our case specifically, it's a little bit more difficult because we have a few major shareholders that they control a big chunk of the company.

Between myself and the Chinese and some of the other shareholders, we own about 50% of the company.

So what happens is the level of liquidity is very low.

So if you're going to come now and you're going to buy a million dollars of shares, share price is going to spike.

And if you're going to sell a million dollars worth of shares,

share price is going to go down and that's a challenge is the lack of liquidity.

So I would look at it sort of as a half private company

That's why, hence, I think there's an opportunity because the company is making a nice progress.

The company doesn't need to raise money.

OK, we can see the milestone coming.

And in about 10 months from now, we're going to have the most important milestone in our history.

We're going to have the result of a 90 days trial when we administer oral insulin.

And that's going to be a very or the most clear cut indication as to the value of this technology.

There is, there is, and it takes a huge amount of effort from the management to put into it.

But even when I spoke to some of the private investors, many of them, they want to see liquidity down the line.

Nobody wants, the problem is currently, if you have a drug and you want to get it to the market in the United States, you need to go through the US FDA.

The US FDA takes you through a via de la rosa that costs you a lot of money and mainly takes you a long time.

Well, if you look at the average time to develop a drug, you're talking about 15, 16 years.

The average, if you're taking also the ones that fail, you're talking about close to a billion dollars to develop a drug.

So the investors say, you know what, I want to enjoy it because it could be that even the drug is going to fail at the end of the day.